Form 4: CEO Jurgi Camblong Sells SOPHiA GENETICS Shares

SOPHiA GENETICS CEO Jurgi Camblong reported a sale of 8,500 ordinary shares for $5.0872 per share, executed under a Rule 10b5-1 trading plan.

Summary

• Jurgi Camblong, CEO of SOPHiA GENETICS SA, sold 8,500 ordinary shares on May 11, 2026.
• The transaction was conducted under a pre-arranged trading plan compliant with Rule 10b5-1(c).
• The weighted average sale price was $5.0872 per share, with individual sales ranging from $4.72 to $5.49.
• Following the transaction, Camblong beneficially owns 3,633,981 ordinary shares directly.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative event due to the insider sale, although the Rule 10b5-1 plan mitigates concerns about opportunistic trading.

Negatives

• CEO Jurgi Camblong sold a significant number of shares (8,500) which could be perceived negatively by the market.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it pertains to a change in beneficial ownership.

Industry Context

StockSavvy.ai notes that insider selling, even under a Rule 10b5-1 plan, can sometimes lead to short-term market scrutiny, though the existence of the plan itself is designed to mitigate concerns about opportunistic trading.

Stakeholder Impact

• Shareholders may view the CEO's sale of shares with caution, potentially impacting short-term stock sentiment.
• The transaction was conducted under a Rule 10b5-1 plan, which is a standard corporate governance practice to allow insiders to trade shares predictably and avoid insider trading concerns.

Key Dates

Keywords

SOPHiA GENETICS, Jurgi Camblong, Form 4, Insider Trading, Rule 10b5-1, Share Sale, CEO Transaction